Clinical Policy: Infliximab (Remicade, Inflectra, Renflexis)
Reference Number: OH.PHAR.254
Effective Date: 08.19
Last Review Date:
Line of Business: Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Infliximab (Remicade®) and its biosimilars, infliximab-dyyb (Inflectra®), and infliximab-abda (Renflexis™) are tumor necrosis factor (TNF) blockers.

FDA Approved Indication(s)
Remicade, Inflectra*, and Renflexis* are indicated for the treatment of:

- Crohn’s Disease (CD):
  - Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active CD who have had an inadequate response to conventional therapy
  - Reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing CD.

- Pediatric CD:
  - Reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active CD who have had an inadequate response to conventional therapy

- Ulcerative Colitis (UC):
  - Reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active UC who have had an inadequate response to conventional therapy

- Pediatric UC (Remicade only):
  - Reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active UC who have had an inadequate response to conventional therapy

- Rheumatoid Arthritis (RA):
  - Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active RA, in combination with methotrexate (MTX)

- Ankylosing Spondylitis (AS):
  - Reducing signs and symptoms in patients with active AS

- Psoriatic Arthritis (PsA):
  - Reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with PsA

- Plaque Psoriasis (PsO):
  - Treatment of adult patients with chronic severe (i.e., extensive and/or disabling) PsO who are candidates for systemic therapy and when other systemic therapies are medically less
appropriate. Infliximab should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

*Renflexis, and Inflectra are approved for all of the above indications except for pediatric UC.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Remicade, Inflectra, and Renflexis are medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Crohn’s Disease (must meet all):
      1. Diagnosis of CD;
      2. Prescribed by or in consultation with a gastroenterologist;
      3. Age ≥ 6 years;
      4. Member meets one of the following (a or b):
         a. Failure of a ≥ 3 consecutive month trial of at least ONE immunomodulator (e.g., azathioprine, 6-mercaptopurine [6-MP], MTX) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
         b. Medical justification supports inability to use immunomodulators (see Appendix E);
      5. If request is for Remicade, member has experienced clinically significant adverse effects or has a contraindication to excipients from Inflectra, and Renflexis;
      6. Dose does not exceed 5 mg/kg at weeks 0, 2, and 6, followed by maintenance dose of 5 mg/kg every 8 weeks.

   Approval duration: 6 months

   B. Ulcerative Colitis (must meet all):
      1. Diagnosis of UC;
      2. Prescribed by or in consultation with a gastroenterologist;
      3. Age ≥ 6 years;
      4. Failure of a ≥ 3 consecutive month trial of azathioprine, 6-MP, or an aminosalicylate (e.g., sulfasalazine) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
      6. If age is ≥ 18 years and request is for Remicade, member has experienced clinically significant adverse effects or has a contraindication to excipients from Inflectra, and Renflexis;
      7. Dose does not exceed 5 mg/kg at weeks 0, 2, and 6, followed by maintenance dose of 5 mg/kg every 8 weeks.

   Approval duration: 6 months
C. Rheumatoid Arthritis (must meet all):
   1. Diagnosis of RA;
   2. Prescribed by or in consultation with a rheumatologist;
   3. Age ≥ 18 years;
   4. Member meets one of the following (a or b):
      a. Failure of a ≥ 3 consecutive month trial of MTX at up to maximally indicated doses, unless contraindicated or clinically significant adverse effect are experienced;
      b. If intolerance or contraindication to MTX (see Appendix D), failure of a ≥ 3 consecutive month trial of at least ONE conventional disease-modifying antirheumatic drug [DMARD] (e.g., sulfasalazine, leflunomide, hydroxychloroquine) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effect are experienced;
   5. Prescribed concomitantly with MTX, or another DMARD if intolerance or contraindication to MTX;
   6. If request is for Remicade, member has experienced clinically significant adverse effects or has a contraindication to excipients from Inflectra, and Renflexis;
   7. Dose does not exceed 3 mg/kg at weeks 0, 2, and 6, followed by maintenance dose of 3 mg/kg every 8 weeks.

Approval duration: 6 months

D. Ankylosing Spondylitis (must meet all):
   1. Diagnosis of AS;
   2. Prescribed by or in consultation with a rheumatologist;
   3. Age ≥ 18 years;
   4. Failure of at least TWO non-steroidal anti-inflammatory drugs (NSAIDs) at up to maximally indicated doses, each used for ≥ 4 weeks unless contraindicated or clinically significant adverse effects are experienced;
   5. If request is for Remicade, member has experienced clinically significant adverse effects or has a contraindication to excipients from Inflectra, and Renflexis;
   6. Dose does not exceed 5 mg/kg at weeks 0, 2, and 6, followed by maintenance dose of 5 mg/kg every 6 weeks.

Approval duration: 6 months

E. Psoriatic Arthritis (must meet all):
   1. Diagnosis of PsA;
   2. Prescribed by or in consultation with a dermatologist or rheumatologist;
   3. Age ≥ 18 years;
   4. If request is for Remicade, member has experienced clinically significant adverse effects or has a contraindication to excipients from Inflectra, and Renflexis;
   5. Dose does not exceed 5 mg/kg at weeks 0, 2, and 6, followed by maintenance dose of 5 mg/kg every 8 weeks.

Approval duration: 6 months
F. **Plaque Psoriasis** (must meet all):
   1. Diagnosis of PsO;
   2. Prescribed by or in consultation with a dermatologist or rheumatologist;
   3. Age ≥ 18 years;
   4. Member meets one of the following (a or b):
      a. Failure of a ≥ 3 consecutive month trial of MTX at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
      b. If intolerance or contraindication to MTX (*see Appendix D*), failure of a ≥ 3 consecutive month trial of cyclosporine or acitretin at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
   5. If request is for Remicade, member has experienced clinically significant adverse effects or has a contraindication to excipients from Inflectra, and Renflexis;
   6. Dose does not exceed 5 mg/kg at weeks 0, 2, and 6, followed by maintenance dose of 5 mg/kg every 8 weeks.

**Approval duration: 6 months**

G. **Other diagnoses/indications**
   1. There are no pharmacy and therapeutic committee approved off-label use criteria for the diagnosis;
   2. Use is supported by one of the following (a, b, or c):
      a. The National Comprehensive Cancer Network (NCCN) Drug Information and Biologics Compendium level of evidence 1 or 2A (*see Appendix D*);
      b. Evidence from at least two high-quality, published studies in reputable peer-reviewed journals or evidence-based clinical practice guidelines that provide all of the following (i – iv):
         i. Adequate representation of the member’s clinical characteristics, age, and diagnosis;
         ii. Adequate representation of the prescribed drug regimen;
         iii. Clinically meaningful outcomes as a result of the drug therapy in question;
         iv. Appropriate experimental design and method to address research questions (*see Appendix E for additional information*);
      c. Micromedex DrugDex® with strength of recommendation Class I, IIa, or IIb (*see Appendix D*);
   3. Prescribed by or in consultation with an appropriate specialist for the diagnosis;
   4. Failure of an adequate trial of at least two FDA-approved drugs for the indication and/or drugs that are considered the standard of care, when such agents exist for the same indication at maximum indicated doses, unless no such drugs exist, at maximum indicated doses, unless contraindicated or clinically significant adverse effect are experienced;
   5. Dosing regimen and duration are within dosing guidelines recommended by clinical practice guidelines and/or medical literature.
6. If request is for Remicade, member has experienced clinically significant adverse effects or has a contraindication to excipients from Inflectra, and Renflexis;

**Approval duration: Duration of request or 6 months (whichever is less)**

II. Continued Therapy
   A. All Indications in Section I (must meet all):
      1. Currently receiving medication via Centene benefit or member has previously met all initial approval criteria;
      2. If request is for Remicade, member has experienced clinically significant adverse effects or has a contraindication to excipients from Inflectra and Renflexis;
      3. Member is responding positively to therapy;
      4. If request is for a dose increase, new regimen does not exceed one of the following (a, b, c, or d):
         a. CD (i or ii):
            i. 5 mg/kg every 8 weeks;
            ii. 10 mg/kg every 8 weeks, if age ≥ 18 years and documentation supports inadequate response to current dose;
         b. UC, PsA, PsO: 5 mg/kg every 8 weeks;
         c. RA (i or ii):
            i. 3 mg/kg every 8 weeks;
            ii. If the request is for an increase in dose or dosing frequency (*dose and frequency should not be increased simultaneously*) from the current regimen, regimen does not exceed 10 mg/kg and/or every 4 weeks, and documentation supports both of the following (a and b):
               a) Member has had an inadequate response to adherent use of Remicade/Inflectra/Renflexis concurrently with MTX or another DMARD;
               b) One of the following (1 or 2):
                  1) Current dosing frequency is every 8 weeks: member has received at least 4 doses (14 weeks of total therapy) of Remicade/Inflectra/Renflexis;
                  2) Current dosing frequency is < every 8 weeks: member has received at least 2 doses of Remicade/Inflectra/Renflexis at the current dosing frequency;
         a. AS: 5 mg/kg every 6 weeks.

**Approval duration: 12 months (If new dosing regimen, approve for 6 months)**

B. Other diagnoses/indications (must meet all):
   1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
   2. If request is for Remicade, member has experienced clinically significant adverse effects or has a contraindication to excipients from Inflectra and Renflexis;
   3. Member is responding positively to therapy;
4. If request is for a dose increase (quantity or frequency), member has been titrated up from the lower dose with documentation of partial improvement, and the new dose does not exceed dosing guidelines recommended by the product information label or clinical practice guidelines and/or medical literature.

Approval duration: Duration of request or 12 months (whichever is less)

III. Diagnoses/Indications for which coverage is NOT authorized:
1. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

<table>
<thead>
<tr>
<th>Abbreviation/Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>6-MP</td>
<td>6-mercaptopurine</td>
</tr>
<tr>
<td>AS</td>
<td>ankylosing spondylitis</td>
</tr>
<tr>
<td>CD</td>
<td>Crohn’s disease</td>
</tr>
<tr>
<td>DMARD</td>
<td>disease-modifying antirheumatic drug</td>
</tr>
<tr>
<td>GI</td>
<td>gastrointestinal</td>
</tr>
<tr>
<td>MTX</td>
<td>methotrexate</td>
</tr>
<tr>
<td>NSAID</td>
<td>non-steroidal anti-inflammatory drug</td>
</tr>
<tr>
<td>PsA</td>
<td>psoriatic arthritis</td>
</tr>
<tr>
<td>PsO</td>
<td>psoriasis</td>
</tr>
<tr>
<td>RA</td>
<td>rheumatoid arthritis</td>
</tr>
<tr>
<td>TNF</td>
<td>tumor necrosis factor</td>
</tr>
<tr>
<td>UC</td>
<td>ulcerative colitis</td>
</tr>
</tbody>
</table>

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>acitretin (Soriatane®)</td>
<td>PsO 25 or 50 mg PO QD</td>
<td>50 mg/day</td>
</tr>
<tr>
<td>azathioprine (Azasan®, Imuran®)</td>
<td>RA 1 mg/kg/day PO QD or divided BID</td>
<td>2.5 mg/kg/day</td>
</tr>
<tr>
<td></td>
<td>CD*, UC* 1.5 – 2 mg/kg/day PO</td>
<td></td>
</tr>
<tr>
<td>corticosteroids</td>
<td>CD* prednisone 40 mg PO QD for 2 weeks or IV 50 – 100 mg Q6H for 1 week</td>
<td>Various</td>
</tr>
<tr>
<td></td>
<td>budesonide (Entocort EC®) 6-9 mg PO QD</td>
<td></td>
</tr>
<tr>
<td>Cuprimine® (d-penicillamine)</td>
<td>RA* Initial dose: 125 or 250 mg PO QD</td>
<td>1,500 mg/day</td>
</tr>
<tr>
<td></td>
<td>Maintenance dose: 500 – 750 mg/day PO QD</td>
<td></td>
</tr>
<tr>
<td>Drug Name</td>
<td>Dosing Regimen</td>
<td>Dose Limit/ Maximum Dose</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-----------------------------------------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>cyclosporine</td>
<td>PsO 2.5 mg/kg/day PO divided BID</td>
<td>PsO, RA: 4 mg/kg/day</td>
</tr>
<tr>
<td>(Sandimmune®, Neoral®)</td>
<td>PsA* 2.5 – 3 mg/kg/day PO QD</td>
<td>PsA: 3 mg/kg/day</td>
</tr>
<tr>
<td></td>
<td>RA 2.5 – 4 mg/kg/day PO divided BID</td>
<td></td>
</tr>
<tr>
<td>hydroxychloroquine</td>
<td>RA* Initial dose: 400 – 600 mg/day PO QD</td>
<td>600 mg/day</td>
</tr>
<tr>
<td>(Plaquenil®)</td>
<td>Maintenance dose: 200 – 400 mg/day PO QD</td>
<td></td>
</tr>
<tr>
<td>leflunomide</td>
<td>PsA* 100 mg/day PO loading dose for 3 days followed by 20 mg/day PO QD</td>
<td>20 mg/day</td>
</tr>
<tr>
<td>(Arava®)</td>
<td>RA 100 mg PO QD for 3 days, then 20 mg PO QD</td>
<td></td>
</tr>
<tr>
<td>6-mercaptopurine</td>
<td>CD*, UC* 50 mg PO QD or 1 – 2 mg/kg/day PO</td>
<td>2 mg/kg/day</td>
</tr>
<tr>
<td>(Purixan®)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>methotrexate</td>
<td>CD*, UC* 15 – 25 mg/week IM or SC</td>
<td>30 mg/week</td>
</tr>
<tr>
<td>(Rheumatrex®)</td>
<td>PsO 10 – 25 mg/week PO or 2.5 mg PO Q12 hr for 3 doses/week</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PsA* 7.5 – 15 mg/week PO</td>
<td></td>
</tr>
<tr>
<td></td>
<td>RA 7.5 mg/week PO, SC, or IM or 2.5 mg PO Q12 hr for 3 doses/week</td>
<td></td>
</tr>
<tr>
<td>NSAIDs (e.g., indomethacin,</td>
<td>AS, PsA Varies</td>
<td>Varies</td>
</tr>
<tr>
<td>ibuprofen, naproxen, celecoxib)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pentasa® (mesalamine)</td>
<td>CD, UC 1,000 mg PO QID</td>
<td>4 g/day</td>
</tr>
</tbody>
</table>
## Clinical Policy

Infliximab, Infliximab-dyyb, Infliximab-abda,

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ridaura® (auranofin)</td>
<td>RA 6 mg PO QD or 3 mg PO BID</td>
<td>9 mg/day (3 mg TID)</td>
</tr>
<tr>
<td>sulfasalazine (Azulfidine®)</td>
<td>PsA* 2 g/day PO QD</td>
<td>PsA: 5 g/day</td>
</tr>
<tr>
<td></td>
<td>RA 2 g/day PO in divided doses</td>
<td>RA: 3 g/day</td>
</tr>
<tr>
<td></td>
<td>UC Initial dose:</td>
<td>UC: 4 g/day</td>
</tr>
<tr>
<td></td>
<td>*Adults: 3 – 4 g/day PO in divided doses (not to exceed Q8 hrs)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>*Pediatrics: 40 – 60 mg/kg/day PO in 3 – 6 divided doses</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maintenance dose:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>*Adults: 2 g PO daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td>*Pediatrics: 30 mg/kg/day PO in 4 divided doses</td>
<td></td>
</tr>
<tr>
<td>tacrolimus (Prograf®)</td>
<td>CD* 0.27 mg/kg/day PO in divided doses or 0.15 – 0.29 mg/kg/day PO</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>PsO 0.05 – 0.15 mg/kg/day PO</td>
<td></td>
</tr>
</tbody>
</table>

*Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

*Off-label

### Appendix C: Contraindications/Boxed Warnings

- **Contraindication(s):**
  - Doses > 5 mg/kg in patients with moderate-to-severe heart failure
  - Re-administration to patients who have experienced a severe hypersensitivity reaction to infliximab products
  - Known hypersensitivity to inactive components of the product or to any murine proteins
- **Boxed warning(s):**
  - Serious infections
  - Malignancy

### Appendix D: General Information

- **Contraindications:**
  - Remicade/Renflexis/Inflectra/Ixifi doses > 5 m/kg should not be administered to patients with moderate to severe heart failure. Remicade doses of 10 mg/kg were shown
Infliximab, Infliximab-dyyb, Infliximab-abda,

to be associated with an increased incidence of death and hospitalization due to worsening heart failure in clinical trials.

- Ankylosing Spondylitis:
  - Several AS treatment guidelines call for a trial of 2 or 3 NSAIDs prior to use of an anti-TNF agent. A two year trial showed that continuous NSAID use reduced radiographic progression of AS versus on demand use of NSAID.

- Definition of failure of MTX or DMARDs
  - Child-bearing age is not considered a contraindication for use of MTX. Each drug has risks in pregnancy. An educated patient and family planning would allow use of MTX in patients who have no intention of immediate pregnancy.
  - Social use of alcohol is not considered a contraindication for use of MTX. MTX may only be contraindicated if patients choose to drink over 14 units of alcohol per week. However, excessive alcohol drinking can lead to worsening of the condition, so patients who are serious about clinical response to therapy should refrain from excessive alcohol consumption.

- Examples of positive response to therapy may include, but are not limited to:
  - Reduction in joint pain/swelling/tenderness
  - Improvement in ESR/CRP levels
  - Improvements in activities of daily living

- PsA: According to the 2018 American College of Rheumatology and National Psoriasis Foundation guidelines, TNF inhibitors or oral small molecules (e.g., methotrexate, sulfasalazine, cyclosporine, leflunomide, apremilast) are preferred over other biologics (e.g., interleukin-17 inhibitors or interleukin-12/23 inhibitors) for treatment-naive disease. TNF inhibitors are also generally recommended over oral small molecules as first-line therapy unless disease is not severe, member prefers oral agents, or TNF inhibitor therapy is contraindicated.

**Appendix E: Medical Justification**

- The following may be considered for medical justification supporting inability to use an immunomodulator for Crohn’s disease:
  - Inability to induce short-term symptomatic remission with a 3-month trial of systemic glucocorticoids
  - High-risk factors for intestinal complications may include:
    - Initial extensive ileal, ileocolonic, or proximal GI involvement
    - Initial extensive perianal/severe rectal disease
    - Fistulizing disease (e.g., perianal, enterocutaneous, and rectovaginal fistulas)
    - Deep ulcerations
    - Penetrating, stricturing or stenosis disease and/or phenotype
    - Intestinal obstruction or abscess
  - High risk factors for postoperative recurrence may include:
    - Less than 10 years duration between time of diagnosis and surgery
    - Disease location in the ileum and colon
    - Perianal fistula
    - Prior history of surgical resection
    - Use of corticosteroids prior to surgery
V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
</table>
| CD, UC     | Initial dose:  
Adults/Pediatrics: 5 mg/kg IV at weeks 0, 2 and 6  
Maintenance dose:  
Adults/Pediatrics: 5 mg/kg IV every 8 weeks.  
For CD: Some adult patients who initially respond to treatment may benefit from increasing the dose to 10 mg/kg if they later lose their response | CD, Adults: 10 mg/kg every 8 weeks  
UC, Adults: 5 mg/kg every 8 weeks  
Pediatrics: 5 mg/kg every 8 weeks |
| PsA        | Initial dose: | 5 mg/kg every 8 weeks |
| PsO        | 5 mg/kg IV at weeks 0, 2 and 6  
Maintenance dose:  
5 mg/kg IV every 8 weeks | |
| RA         | In conjunction with MTX  
Initial dose:  
3 mg/kg IV at weeks 0, 2 and 6  
Maintenance dose:  
3 mg/kg IV every 8 weeks  
Some patients may benefit from increasing the dose up to 10 mg/kg or treating as often as every 4 weeks | 10 mg/kg every 4 weeks |
| AS         | Initial dose:  
5 mg/kg IV at weeks 0, 2 and 6  
Maintenance dose:  
5 mg/kg IV every 6 weeks | 5 mg/kg every 6 weeks |

VI. Product Availability

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infliximab (Remicade)</td>
<td>Single-use vial: 100 mg/20 mL</td>
</tr>
<tr>
<td>Infliximab-dyyb (Inflectra)</td>
<td>Single-use vial: 100 mg/20 mL</td>
</tr>
<tr>
<td>Infliximab-abda (Renflexis)</td>
<td>Single-use vial: 100 mg/20 mL</td>
</tr>
</tbody>
</table>

VII. References


15. PsA: According to the 2018 American College of Rheumatology and National Psoriasis Foundation guidelines, TNF inhibitors or oral small molecules (e.g., methotrexate, sulfasalazine, cyclosporine, leflunomide, apremilast) are preferred over other biologics (e.g., interleukin-17 inhibitors or interleukin-12/23 inhibitors) for treatment-naive disease. TNF inhibitors are also generally recommended over oral small molecules as first-line therapy unless disease is not severe, member prefers oral agents, or TNF inhibitor therapy is contraindicated.

**Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-
date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPSC Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J1745</td>
<td>Injection, infliximab, excludes biosimilar, 10 mg</td>
</tr>
<tr>
<td>Q5103</td>
<td>Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg</td>
</tr>
<tr>
<td>Q5104</td>
<td>Injection, infliximab-abda, biosimilar, (renflexis), 10 mg</td>
</tr>
</tbody>
</table>

**Reviews, Revisions, and Approvals**

Policy split from CP.PHAR.86.ArthritisTreatments, CP.PHAR.85.Psoriasis Treatments, CP.PHAR.87.IBD Treatment_4_

- Added the biosimilar Inflectra (approved for all Remicade indications with the exception of pediatric UC).
- CD, UC, RA, PsA, AS, PsO: Removed criteria related to HBV, malignant disease, concomitant use with other biologics, and concurrent administration of live vaccines; added dosing.
- CD: modified criteria requiring failure of immunomodulator, corticosteroids or aminosalicylate to failure of “corticosteroid, with or without immunomodulator” per 2014 AGA Clinical decision tool.
- RA: changed age requirement to 18; modified criteria to require trial of MTX, unless contraindicated; added sulfasalazine and hydroxychloroquine as an alternative to MTX if contraindicated; Required trial of Humira AND Enbrel instead of one or the other. Added option for other DMARD if concomitant admin of MTX contraindicated.
- AS: added option of trial of a different biologic in addition to NSAIDs. Required trial of Humira AND Enbrel instead of one or the other.
- PsA: Added requirements for failure of a different biologic or 2 or more DMARDS, not including Otezla.
- PsO: removed duration of trial for topical and phototherapy; Added option for trial of a different biologic. Required trial of Humira and Enbrel, instead of previous requirement of Humira or Enbrel.
- Re-auth: combined into All Indications; added criteria for dosing and reasons to discontinue; for PsO changed efficacy criteria related to Psoriasis Area and Severity Index (PASI)-75 to general efficacy statement.
- Modified approval duration to 6 months for initial and 12 months for renewal.
- Added preferencing for Inflectra prior to allowing Remicade, except for UC patients aged 6-18.
- CD: Removed corticosteroid as an option for trial/failure.
- UC: removed aminosalicylates and corticosteroids as potential acceptable first-line therapies.

<table>
<thead>
<tr>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.16</td>
<td>07.16</td>
</tr>
<tr>
<td>11.16</td>
<td>12.16</td>
</tr>
</tbody>
</table>
### Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Description</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>PsA: Preferred trial of MTX above other DMARDs. Specialist review by dermatologist, rheumatologist, and gastroenterologist.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Humira preferencing in pediatric Crohn’s is removed.</td>
<td>03.17</td>
<td></td>
</tr>
<tr>
<td>Converted to new template. Removed limitations based on labeled warnings and precautions. RA: modified the RA diagnostic criteria from requiring one or more of the following: ≥ 5 inflamed joints, elevated ESR and/or CRP; positive rheumatoid factor and/or anticyclic citrullinated peptide (CCP) antibodies; evidence of inflammation on plain radiography of the hands, wrists, or feet, such as osteopenia and/or periarticular swelling, to the ACR diagnostic criteria. PsA: changed option of contraindication to hydroxychloroquine to cyclosporine. PsO: removed redirection to Enbrel and Humira. AS: added prescriber restriction. CD: updated list of poor prognostic indicators. UC: change required trials form immunomodulator to specifically thiopurines and removed MTX as example of acceptable trial; removed redirection to Humira. Added Renflexis.</td>
<td>07.17</td>
<td>07.17</td>
</tr>
<tr>
<td>2Q 2018 annual review: removed TB testing requirement from all criteria; removed requirements for specific criteria relating to diagnosis for CD and PsO; modified gastroenterologist specialty requirement to gastrointestinal specialist for CD/UC; modified preferencing for infliximab products for all indications, added aminosalicylate as an option for trial and failure for UC; modified trial and failure for RA to at least one conventional DMARD; added requirement for concomitant use of MTX or another DMARD for RA; removed trial and failure of phototherapy and topical therapy for PsO; modified trial and failure for PsO to require methotrexate (or another agent if methotrexate is not tolerated or contraindicated); added specific max dosing requirements for continued therapy approval; references reviewed and updated.</td>
<td>02.27.18</td>
<td>05.18</td>
</tr>
<tr>
<td>4Q 2018 annual review: added HIM; modified prescriber specialist from GI specialist to gastroenterologist for CD and UC; added trial and failure of immunosuppressants, or medical necessity for use of biologics in CD; allowed bypassing conventional DMARDs for axial PsA and required trial of NSAIDs; references reviewed and updated.</td>
<td>09.04.18</td>
<td>11.18</td>
</tr>
<tr>
<td>Removed redirections to Humira and/or Enbrel for all indications per SDC decision in line with previously approved clinical guidance.</td>
<td>12.21.18</td>
<td></td>
</tr>
<tr>
<td>2Q 2019 annual review: removed trial and failure requirement of conventional DMARDs (e.g., MTX)/NSAIDs for biologic DMARDs 03.05.19 05.19</td>
<td>03.05.19</td>
<td>5.19</td>
</tr>
<tr>
<td>Converted to an Ohio specific policy; added continuation therapy needs to be changed to a Inflectra or Renflexis unless contraindicated</td>
<td>05.15.19</td>
<td>7.18.19</td>
</tr>
</tbody>
</table>
Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members
and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.

Meera Patel-Zook., Senior Director Pharmacy Operations Approval on file
Ronald Charles, Vice President of Medical Affairs Approval on file

**POLICY AND PROCEDURE APPROVAL**

The electronic approval retained in RSA Archer, the Company's P&P management software, is considered equivalent to a signature.